HOWL Earnings & Financial Statements
Werewolf Therapeutics, Inc.
$0.98
-$0.01(-1.12%)
55
Overall
60
Value
83
Tech
23
Quality
Market Cap
$47.63M
Volume
664.07K
52W Range
$0.27 - $1.83
Target Price
$4.67
HOWL earnings and financial statements: Werewolf Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
HOWL Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | $1.89M | $1.56M | $16.40M | - |
| Operating income | -$60.68M | -$73.59M | -$40.50M | -$56.06M | -$50.09M |
| EBITDA | -$53.13M | -$63.16M | -$33.97M | -$51.10M | -$49.25M |
| Net income | -$60.82M | -$70.52M | -$37.37M | -$53.81M | -$49.98M |
| EPS (diluted) | $-1.33 | $-1.63 | $-1.05 | $-1.86 | $-10.94 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $69.40M | $126.93M | $174.83M | $160.25M | $179.25M |
| Total liabilities | $44.59M | $53.54M | $63.46M | $37.91M | $26.46M |
| Shareholders’ equity | $24.80M | $73.39M | $111.37M | $122.34M | $152.79M |
| Cash and equivalents | $57.05M | $111.00M | $134.34M | $129.31M | $157.53M |
| Long-term debt | $7.68M | $35.53M | $43.65M | $12.60M | $14.59M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$60.29M | -$56.19M | -$32.61M | -$40.60M | -$42.88M |
| Capital expenditure | - | -$254.0K | -$769.0K | -$3.61M | -$498.0K |
| Free cash flow | -$60.29M | -$56.44M | -$33.38M | -$44.21M | -$43.37M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | HOWL | $0.98 | -1.1% | 664.07K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Werewolf Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW